Fate Therapeutics Q3 2022 Earnings Report

FT596+R enrollment is ongoing in the three-dose escalation cohort for R/R BCL and community sites are being activated for investigation of FT596+R-CHOP in newly-diagnosed patients with aggressive BCL.

Positive feedback was received from the FDA under FT516 RMAT designation for derivation of a clonal engineered master iPSC bank and for potential registrational study design.

Preclinical data of FT555, a GPRC5D-targeted CAR NK cell product candidate for R/R MM under the Janssen collaboration, will be presented at ASH, and Janssen has exercised its commercial option for an additional product candidate targeting an undisclosed hematologic malignancy antigen.

14 abstracts were selected for presentation at ASH, including interim Phase 1 dose-escalation data of FT576 for R/R MM and of FT819 for R/R BCL, and 12 abstracts were selected for presentation at SITC, including interim Phase 1 dose-escalation data of FT536 and FT538 for advanced solid tumors.